Effectiveness and safety of paclitaxel-eluting stents in patients with ST-segment elevation acute myocardial infarction.
OBJECTIVE
The efficacy of paclitaxel-eluting stents (PES) in patients with ST-segment elevation acute myocardial infarction (STEMI) has not been demonstrated yet. The aim of the present study was to evaluate the efficacy and safety of PES in patients with STEMI.


RESULTS
A meta-analysis from three randomised trials that compared PES and bare-metal stents in patients with STEMI was performed. Overall, 925 patients were included: 459 allocated to PES, and 466 to bare-metal stents (BMS). The rates of major adverse events (i.e. death, reinfarction, and target vessel revascularisation at 6-12 month follow-up) was compared for patients with PES and BMS. Compared to patients with BMS, a significant reduction in the incidence of events (9.1% vs. 13.9%, p=0.02; OR 0.62; 95%, CI: 0.41-0.93), and target vessel revascularisation (4.7% vs. 8.3%, p=0.03; OR 0.54; 95%, CI 0.31-0.94) was found in patients with PES. The rates of death and reinfarction were similar in BMS and DES patients.


CONCLUSIONS
The use of PES in patients with STEMI is associated with a significant reduction in MACE and need for new revascularisations.
Moreno
Raúl
R
Division of Interventional Cardiology, University Hospital La Paz, Madrid, Spain.
Spaulding
Christian
C
Jan Laarman
Gert
G
Tierala
Ilkka
I
Kaiser
Christoph A
CA
Lopez-Sendon
Jose-Luis
JL